Boehringer Ingelheim has announced the initiation of a Phase 2 clinical trial of its BI 1265162 inhaled epithelial sodium channel (ENaC) inhibitor delivered via the Respimat SMI plus standard of care in cystic fibrosis patients.
The study is expected to enroll 98 patients aged 12 and over and will compare twice daily doses of BI 1265162 inhalation solution to placebo. The primary endpoint is change in percent predicted trough FEV1 from baseline over 4 weeks.
Boehringer Ingelheim Head of Medicine, Therapeutic Area Inflammation, Kay Tetzlaff commented, “We are pleased to enroll our first patient into this Phase 2 trial, and we hope our ENaC inhibitor will be proven to help people affected by cystic fibrosis. Boehringer Ingelheim is committed to researching new treatments that address serious unmet needs. We are hopeful that this treatment, along with its delivery method, will make an important difference for patients affected by this debilitating condition.”
Read the Boehringer Ingelheim press release.
